Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Octreotide acetate |
| Trade Name | Sandostatin Lar Depot |
| Synonyms | SMS 201-995 |
| Drug Descriptions |
Sandostatin Lar Depot (octreotide acetate) mimics the activity of somatostatin, which may control the growth of neuroendocrine tumors (PMID: 26605828). Sandostatin Lar Depot (octreotide acetate) is FDA approved for symptom control in patients with carcinoid tumors and VIPomas (FDA.gov). |
| DrugClasses | |
| CAS Registry Number | 79517-01-4 |
| NCIT ID | C53447 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Cixutumumab + Everolimus + Octreotide acetate | Cixutumumab Everolimus Octreotide acetate | 0 | 0 |
| Debio 4126 + Octreotide acetate | Debio 4126 Octreotide acetate | 0 | 1 |
| Everolimus + Octreotide acetate | Everolimus Octreotide acetate | 0 | 1 |
| Lutetium Lu 177 dotatate + Octreotide acetate | Lutetium Lu 177 dotatate Octreotide acetate | 0 | 2 |
| Octreotide acetate | Octreotide acetate | 0 | 4 |